Risk of Coronary Heart Disease in People with Chronic Obstructive Pulmonary Disease: A Meta-Analysis

Wang, Jia-Jie

doi:10.2147/copd.s331505

Cited by 9 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coronary heart disease (CHD) and chronic obstructive pulmonary disease (COPD) currently determine the main structure of morbidity and mortality in the world [1,2,3,4].…”

Section: Introductionmentioning

confidence: 99%

“…A large percentage of this burden is found in low and middle income countries. This accounts for nearly 7 million deaths and 129 million DALYs annually and is a huge global economic burden [3]. Various registries show that the annual total mortality is 1.2-2.4% among all patients with CHD, and 0.6-1.4% of patients die annually from fatal cardiovascular complications [5].…”

Section: Introductionmentioning

confidence: 99%

“…Today, COPD is the 3rd leading cause of death in the world; about 2.8 mln people die due to the COPD every year, which is 4.8% of all causes of death [1]. About 50-80% of COPD patients die due to respiratory causes, and most commonly during exacerbations [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vaccine Prevention of Pneumococcal Infection Among Patients With Chronic Obstructive Pulmonary Disease and Coronary Heart Disease –- A 10-year Horizon of Effectiveness

Ignatova,

Avdeev,

Antonov

et al. 2024

Preprint

View full text Add to dashboard Cite

Summary: The article provides an analysis of the clinical effectiveness of the use of the 13-valent conjugate pneumococcal vaccine (PCV13) among patients with comorbidity of chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD). The main objective of this study was to assess the effectiveness of PCV13 on the incidence of community-acquired pneumonia (CAP), as well as the impact on the survival rates of patients with COPD and CHD over fa 10-year period. Materials and methods: 500 male patients with COPD and CHD were included in the study. The primary endpoint was the incidence of CAP during 10 years of follow-up. Secondary endpoints were any-cause of mortality, exacerbations, hospitalizations during 10 years of follow-up and also the dynamics of dyspnea according to mMRC, forced expiratory volume in the first second (FEV1), dynamics of changes in 6MWD, dynamics of changes in functional class of angina pectoris (FC). The 13-valent conjugated pneumococcal vaccine (Prevenar 13) has utilised for immunization. Results and conclusions: PСV13 vaccination has a significant impact on patient survival, at least during the 10-year follow-up period. The utilising of the 13-valent conjugated pneumococcal vaccine leads to a significant reduction of the high morbidity for CAP among patients with COPD, as well as with COPD and CHD. Vaccination leads to the stabilization of the main clinical and functional parameters, including during a 10-year perspective. Recommendations to include pneumococcal vaccines in clinical guidelines and immunization programs should be mandatory and prioritized.

show abstract

“…Coronary heart disease (CHD) and chronic obstructive pulmonary disease (COPD) currently determine the main structure of morbidity and mortality in the world [1,2,3,4].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccine Prevention of Pneumococcal Infection Among Patients With Chronic Obstructive Pulmonary Disease and Coronary Heart Disease –- A 10-year Horizon of Effectiveness

Ignatova,

Avdeev,

Antonov

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The П оліморбідність є однією з особливостей сучасної клініки внутрішніх хвороб, а ішемічна хвороба серця (ІХС), артеріальна гіпертензія (АГ) і хронічне обструктивне захворювання легень (ХОЗЛ) вважаються найбільш поширеними захворюваннями дорослого населення розвинутих країн. Доволі часто зустрічаються пацієнти, у яких ХОЗЛ поєднується із синдромом обструктивного апное сну (СОАС), а серцево-судинна коморбідність нерідко присутня при кожному з них [8,9,25].…”

unclassified

“…• підвищення тонусу симпатичної нервової системи, • інтермітуюча гіпоксемія, • оксидативний стрес, • системне запалення, • ендотеліальна дисфункція, • метаболічні порушення, • зміни внутрішньогрудного тиску [16,17,19,23,25]. Поєднання ХОЗЛ та СОАС взаємно обтяжує перебіг цих нозологій та пов'язане з більш несприятливим прогнозом, ніж будь-яке з цих захворювань окремо [21,24].…”

unclassified

Chronic Obstructive Pulmonary Disease and Sleep Apnea Syndrome – a Multidisciplinary Problem of Clinical Medicine

Chaplynska,

Rudnyk,

Havrysh

et al. 2023

FMEP

View full text Add to dashboard Cite

Obstructive sleep apnea syndrome (OSAS) and chronic obstructive pulmonary disease (COPD) are more common pathologies in clinical practice, which are accompanied very often by cardiovascular comorbidity. The objective: to analyze the clinical features of chronic obstructive pulmonary disease course in combination with the risk of sleep apnea syndrome. Materials and methods. 47 patients with COPD III degree of bronchial obstruction, group E participated in the study: 9 (19.1%) women and 38 (80.9%) men. The study participants were divided into two groups: I group (COPD) – 32 persons, II group (COPD + apnea syndrome) – 15 individuals. Clinical, spirographic laboratory, X-ray, ultrasound, and electrocardiographic examinations were performed to the patients, the STOP-Bang questionnaire was used to determine the risk of sleep apnea syndrome development, and the influence of bronchial obstruction on the daytime sleepiness (Epworth scale) and depression (Beck questionnaire) was studied. Results. The analysis of the results of the study presented that among the examined patients with COPD 32 (68.1%) subjects were identified with a high risk of sleep apnea syndrome. In this cohort of patients there were signs of daytime sleepiness according to the Epworth scale, and according to the Beck questionnaire they scored more than 10 points, that is, a mild level of depression of situational or neurotic origin was found. It was found that among patients with COPD in combination with the risk of night apnea (II group), coronary heart disease was diagnosed in 24 (75%) cases, arterial hypertension – in 22 (68.8%) cases, diabetes – in 15 (46.9%). At the same time, the prevalence of these nosologies in patients with COPD without the risk of night apnea was significantly (p<0.05) lower. The Charlson comorbidity index in patients with COPD and risk of apnea was within 3–4 points, 10-year survival was within 77–53%. Conclusions. The high risk of apnea syndrome according to the results of the screening questionnaire, excessive daytime sleepiness, and depressive states in patients with COPD should prompt primary care physicians to refer such patients to a comprehensive polysomnography examination to confirm OSAS. After all, COPD, OSAS and cardiovascular comorbidity are characterized by a more unfavorable clinical course and prognosis than each of these diseases separately.

show abstract

An exploration of the connection between COVID-19 and cardiovascular disease (CVD) in European countries

Pourshir Sefidi,

Mooney

2024

J Public Health (Berl.)

View full text Add to dashboard Cite

Aim This study aims to extend the research on the connection between COVID-19 and cardiovascular disease (CVD) by exploring this link at a macro level across the continent of Europe. We aim to highlight the virus’s detrimental effects on heart health at both country and continental levels. Subject and methods Utilizing data from the SHARE survey, we investigated the heart health impacts of COVID-19 on individuals aged 50 and over in 26 European countries. A Bayesian hierarchical logistic regression (BHLR) model was employed to assess country-level and continent-level effects, enabling us to account for geographical variations and estimate the overall continental impact. Results Our findings indicate a 20% average increase in CVD risk post-COVID-19 infection, associated with other risk factors such as hypertension, diabetes, chronic lung disease, and elevated BMI. Hypertension was particularly notable as a significant risk factor. Conclusions This study provides a comprehensive overview of how COVID-19 interacts with cardiovascular health risks across Europe. It reveals significant variability in the virus’s impact on heart health across different countries compared to the overall effect observed at the continental level. These insights contribute to a broader understanding of COVID-19’s implications for public health policy and individual risk management in the context of cardiovascular health.

show abstract

Risk of Coronary Heart Disease in People with Chronic Obstructive Pulmonary Disease: A Meta-Analysis

Cited by 9 publications

References 17 publications

Vaccine Prevention of Pneumococcal Infection Among Patients With Chronic Obstructive Pulmonary Disease and Coronary Heart Disease –- A 10-year Horizon of Effectiveness

Vaccine Prevention of Pneumococcal Infection Among Patients With Chronic Obstructive Pulmonary Disease and Coronary Heart Disease –- A 10-year Horizon of Effectiveness

Chronic Obstructive Pulmonary Disease and Sleep Apnea Syndrome – a Multidisciplinary Problem of Clinical Medicine

An exploration of the connection between COVID-19 and cardiovascular disease (CVD) in European countries

Contact Info

Product

Resources

About